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Human anti-neutrophil cytoplasm autoantibodies to proteinase 3
(PR3-ANCA) bind to neutrophils
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Human anti-neutrophil cytoplasm autoantibodies to proteinase
3 (PR3-ANCA) bind to neutrophils.
Background. Recently, the in vivo pathogenic role of anti-
neutrophil cytoplasm autoantibodies (ANCA) in ANCA-
associated vasculitis has been challenged by Abdel-Salam et al.
In their report, they observed that ANCA directed against pro-
teinase 3 (PR3) cannot bind to their target autoantigen PR3 on
circulating neutrophils (PMN). Here we present evidence that
human PR3-ANCA do specifically bind to PMN that express
PR3 on their membrane.
Methods. PMN were isolated from donors showing bimodal
membrane PR3 expression on their PMN (N = 3). TNFa-
primed PMN or PMA-stimulated PMN were incubated with
serum or plasma from PR3-ANCA–positive patients with We-
gener’s granulomatosis (WG) (N = 8) or healthy controls
(N = 8). Binding of IgG in serum or plasma samples to PMN
was assessed by indirect immunofluorescence.
Results. Binding of IgG in undiluted plasma or serum from
PR3-ANCA–positive WG-patients to PMN was significantly in-
creased compared to plasma or serum from healthy controls. Di-
lution of plasma and serum showed concentration-dependent
binding of IgG. Double staining for PR3 and IgG demonstrated
that IgG in plasma or serum from PR3-ANCA–positive patients
only bound to those PMN that expressed PR3, and not to PMN
that lacked PR3 expression on their membrane.
Conclusion. PR3-ANCA in undiluted serum or plasma from
PR3-ANCA–positive WG patients bind to TNFa- primed and
PMA-stimulated PMN that express PR3 on their membrane.
Therefore, the hypothesis that PR3-ANCA can bind and acti-
vate primed PMN is still the most attractive explanation for the
contribution of PR3-ANCA to the pathogenesis of Wegener’s
granulomatosis.
In anti-neutrophil cytoplasm autoantibodies (ANCA)-
associated vasculitis, ANCA have been suggested to be
pathogenic as ANCA titers correlate with disease activity
[1–3], although this has been questioned as well [4]. Ex-
perimentally, a single injection of antimouse MPO anti-
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bodies in mice induced focal, necrotizing, and crescentic
glomerulonephritis, supporting their pathogenic poten-
tial [5]. The proposed pathogenic role of ANCA is further
supported by observations demonstrating that in vitro
ANCA can activate primed polymorphonuclear leuko-
cytes (PMN), leading to their degranulation and oxy-
gen radical production [6, 7]. In patients with Wegener’s
granulomatosis (WG), ANCA most frequently target
proteinase 3 (PR3). Binding of ANCA to their target
antigen on PMN is a prerequisite for activation of PMN
by ANCA, as has been shown in many studies [6–9].
Recently, Abdel-Salam et al suggested that, in vivo,
PR3-ANCA cannot bind to their target autoantigen
proteinase 3 on PMN [10]. They showed, by indi-
rect immunofluorescence, lack of ANCA-bound circu-
lating PMN in patients with active WG. In addition, no
specific binding of immunoglobulin G (IgG) in PR3-
ANCA–containing plasma to phorbol-myristate-acetate
(PMA)-activated PMN could be detected. Only puri-
fied IgG fractions from PR3-ANCA–positive patients
showed specific binding to PR3. This binding, how-
ever, was greatly reduced when low concentrations of
serum, purified IgG, or albumin were introduced. Based
upon these observations, the authors suggested that PR3-
ANCA have a low affinity toward membrane-bound PR3.
Therefore, they stated that PR3-ANCA cannot be po-
tent activators of PMN and, as such, cannot contribute
substantially to the pathogenesis of WG. As this conclu-
sion challenges the relevance of many studies on ANCA-
associated vasculitis, we undertook the present study in
order to further explore binding of PR3-ANCA to PMN.
The results are fully compatible with binding of human
PR3-ANCA to PMN.
METHODS
Patient sera and plasma samples
Serum (N = 8) and paired plasma samples (N = 8)
of PR3-ANCA–positive patients were selected based on
moderate to high titers of PR3-ANCA [ranging from
1:160 to 1:640, as determined by indirect immunoflu-
orescence (IIF)], and were stored at −20◦C until use.
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PR3-ANCA–positive patients all had Wegener’s gran-
ulomatosis based upon the Chapel Hill criteria [11].
PR3-ANCA specificity was assessed by PR3-specific
enzyme-linked immunosorbent assay (ELISA), as de-
scribed previously [12]. Control serum and plasma sam-
ples were obtained from 8 different healthy individuals.
The study was approved by the local Ethical Committee.
Neutrophil isolation and priming
Neutrophils of 3 healthy individuals were isolated
from heparinized blood by centrifugation on Lympho-
prep (Nycomed, Oslo, Norway). All these individu-
als showed bimodal expression of PR3 on their PMN.
Bimodal distribution of PR3 expression on PMN is a
well-established phenomenon [13, 14], representing the
presence of 2 subsets of PMN within 1 donor: a subset of
PMN expressing PR3 on their membrane (mPR3+ PMN)
and a subset of PMN lacking expression of PR3 on their
membrane (mPR3− PMN) [13, 14]. Erythrocytes were re-
moved twice by hypotonic lysis with ice-cold ammonium
chloride. Thereafter, cells were washed with ice-cold
Hanks’ balanced salt solution (HBSS) without Ca2+ and
Mg2+ (Life Technologies, Breda, The Netherlands), and
resuspended in HBSS with Ca2+ and Mg2+ (1.107/mL).
This was followed by priming with 10 ng/mL tumor necro-
sis factor a (TNFa) for 15 minutes at 37◦C, or stimulation
with 1 lg/mL phorbol-myristate acetate (PMA; Sigma,
Zwijndrecht, The Netherlands) for 20 minutes at 37◦C.
In some experiments, Fcc-receptors on PMN were sat-
urated by incubation with goat-derived heat-aggregated
IgG (0.5 mg/mL) for 15 minutes at 4◦C. PMN were sub-
sequently washed with phosphate-buffered saline (PBS).
Assessment of binding of PR3-ANCA
Neutrophils (1.106) were incubated with 100 lL undi-
luted serum or plasma and 10 lg/mL mouse antihuman
PR3 monoclonal antibody (PR3 G-3) [15] for 30 min-
utes at room temperature. In control experiments, an ir-
relevant IgG1 monoclonal antibody was used as isotype
control (IQProducts, Groningen, The Netherlands). In
addition, experiments were repeated with another mouse
antihuman PR3 monoclonal antibody (PR3.12.8) [9, 15,
16] instead of the anti-PR3 G-3 MoAb. After incubation,
cells were washed twice with 3 mL PBS, and incubated
for 30 minutes at room temperature with rabbit antihu-
man IgG-FITC F(ab′)2 antibodies (1:50; Dako, Glostrup,
Denmark) and with PE-conjugated goat antimouse
antibodies (1:50; Southern Biotechnology Associates,
Inc., Birmingham, AL, USA). Subsequently, cells were
washed with 3 mL PBS and fixed in 1% paraformalde-
hyde containing PBS on ice. Flowcytometric analysis
was performed on an ELITE flow cytometer (Becton
Dickinson Immunocytometry Systems, Alphen aan den
Rijn, The Netherlands). PR3-restricted binding of IgG
from sera or plasma was assessed as follows. First, sub-
populations of PMN showing either surface expression of
PR3 or lacking PR3 expression were detected based on
mouse anti-PR3 MoAb binding. These subpopulations
were subsequently gated as mPR3+ or mPR3− PMN, re-
spectively. Negligible binding of IgG in plasma or serum
from PR3-ANCA–positive patients was observed on the
mPR3− PMN subpopulation. Mean fluorescence inten-
sity (MFI) of binding of IgG in plasma or serum to the
gated mPR3− PMN subpopulation was subtracted from
MFI of binding of IgG in plasma or serum to the gated
mPR3+ PMN subpopulation.
Statistics
Statistical analysis was performed using the nonpara-
metric Mann-Whitney test, and GraphPad Prism, version
3.0 (GraphPad Prism Software, San Diego, CA, USA).
RESULTS
TNFa-primed PMN of a donor with bimodal PR3 ex-
pression were incubated with undiluted serum or plasma
samples from PR3-ANCA–positive patients and healthy
controls. In these experiments, PMN were coincubated
with mouse anti-PR3 MoAbs to assess PR3-restricted
binding, as described in Methods. In Figure 1, a rep-
resentative dot plot of double-staining is presented,
showing that binding of IgG in serum or plasma from
PR3-ANCA–positive patients is restricted to those cells
that express PR3 on their membrane. Binding of IgG
in undiluted serum (mean MFI 30.4 ± 9.1, N = 8) or
undiluted plasma (mean MFI 58.1 ± 9.2, N = 8) from
PR3-ANCA–positive patients to primed PMN was sig-
nificantly increased in comparison to undiluted serum
or plasma from healthy controls (mean MFI 4.3 ± 0.7,
N = 8 and mean MFI 2.9 ± 0.6, N = 8, respectively; P =
0.003 and P = 0.001, respectively) (donor #1) (Fig. 2).
Comparable results were obtained when using another
PMN donor (donor #2, Fig. 2). Furthermore, 4 plasma
samples from PR3-ANCA–positive patients were serially
diluted and showed concentration-dependent binding of
IgG to primed PMN (Fig. 3). To explore differences in
IgG binding to PR3 on PMN due to different preincu-
bation procedures, TNFa-primed PMN, as well as PMA-
stimulated PMN, were used. Binding of IgG in undiluted
serum or plasma samples from PR3-ANCA–positive pa-
tients (mean MFI 26.9 ± 11.8, N = 8 and mean MFI 30.9
± 7.7, N = 8, respectively) to PMA-stimulated PMN was
also significantly increased compared to serum or plasma
samples from healthy controls (mean MFI 2.6 ± 0.8, N =
8, and mean MFI 3.9±1.2, N =8, respectively; P =0.0093,
P = 0.0006, respectively) (Fig. 4). Finally, to exclude bind-
ing of IgG to Fcc-receptors, we saturated Fcc-receptors
on PMN using goat-derived heat-aggregated IgG (0.5 mg/
mL). Also after saturating Fcc-receptors, binding of IgG
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Fig. 1. PR3-restricted binding of IgG in serum or plasma samples from PR3-ANCA–positive patients to PMN. (A) Viable TNFa-primed PMN
were selected by gating using FSC/SSC dot plot. (B) Representative dot plot of TNFa-primed PMN that were stained for binding of IgG from
undiluted plasma of a healthy control and for anti-PR3 mouse MoAb (PR3.G-3) binding [15]. MFI of antihuman IgG-FITC staining and antimouse
PE staining are represented on the x- and y-axes, respectively. Binding of anti-PR3 MoAb demonstrates typical bimodal PR3 expression, whereas
IgG from healthy controls does not bind. (C) Representative dot plot of TNFa-primed PMN that were stained for IgG binding from undiluted plasma
from a PR3-ANCA–positive patient and for anti-PR3 mouse MoAb (PR3.G-3) binding. MFI of antihuman IgG-FITC staining and antimouse PE
staining are represented on the x- and y-axes, respectively. Binding of anti-PR3 MoAb demonstrates typical bimodal PR3 expression. IgG from
PR3-ANCA–positive patients show the same pattern of binding. (D) Overlay of IgG binding from undiluted plasma of a healthy control (gray
peak) and from a PR3-ANCA–positive WG patient (black line).
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Fig. 2. Binding of IgG in serum or plasma from PR3-ANCA–positive
patients and healthy controls to TNFa-primed PMN. TNFa-primed
PMN of 2 bimodal donors were incubated for 30 minutes at room
temperature with undiluted sera or paired plasma samples from PR3-
ANCA–positive patients (N = 8) and healthy controls (N = 8). PMN
were coincubated with mouse anti-PR3 MoAb to assess PR3-restricted
binding, as described in Methods. Subsequently, cells were washed twice
and incubated with FITC-conjugated rabbit antihuman IgG and PE-
conjugated goat antimouse IgG. On the y-axis, the mean fluorescence
intensity (MFI) values of the binding experiments are depicted. Values
are given as mean ± standard error of the mean (SEM).
from plasma samples of PR3-ANCA–positive patients
(mean MFI 69.3 ± 6.9, N = 3) was significantly higher
compared to plasma samples of healthy controls (mean
MFI 16.7 ± 4.7, N = 3; P < 0.05) (Fig. 5).
DISCUSSION
In this study we demonstrate that PR3-ANCA in undi-
luted serum or plasma bind to TNFa-primed or PMA-
activated PMN. In addition, we show that the amount of
binding of PR3-ANCA to primed PMN expressing PR3
on their membrane is dilution dependent.
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Fig. 3. Concentration-dependent IgG binding in serially diluted
plasma samples from PR3-ANCA–positive patients to TNFa-primed
PMN. Plasma samples of PR3-ANCA–positive patients (N = 4) were
serially diluted in PBS. TNFa-primed PMN were incubated for 30 min-
utes at room temperature with the respective diluted samples. PMN
were coincubated with mouse anti-PR3 MoAb to assess PR3-restricted
binding, as described in Methods. Subsequently, cells were washed twice
and incubated with FITC-conjugated rabbit antihuman IgG and PE-
conjugated goat antimouse IgG. Results were compared with that of
undiluted plasma samples from healthy controls (N = 4). On the y-axis,
mean fluorescence intensity (MFI) values of the binding experiments
are depicted. Values are given as mean ± standard error of the mean
(SEM).
Our results seem to be in contrast with the findings
of Abdel-Salam et al, who showed that binding of IgG
in plasma from PR3-ANCA–positive patients to stimu-
lated PMN did not differ significantly from binding of
IgG in plasma derived from WG patients negative for
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Fig. 4. Comparison of binding of IgG in serum or plasma from PR3-
ANCA–positive patients to TNFa-primed or PMA-stimulated PMN.
PMN from a donor with bimodal PR3 expression were primed with
TNFa (10 ng/mL) or stimulated with PMA (1lg/mL), and subsequently
incubated for 30 minutes at room temperature with undiluted serum or
paired plasma samples from PR3-ANCA–positive patients (N = 8) and
healthy controls (N = 8). PMN were coincubated with mouse anti-PR3
MoAb to assess PR3-restricted binding, as described in Methods. Sub-
sequently, cells were washed twice and incubated with FITC-conjugated
rabbit antihuman IgG and PE-conjugated goat antimouse IgG. On the
y-axis, mean fluorescence intensity (MFI) values of the binding exper-
iments are depicted. Values are given as mean ± standard error of the
mean (SEM).
PR3-ANCA or healthy donors. PR3-ANCA–positive pa-
tients were defined as patients with titers of ≥1:160 [anti-
PR3 >100 U (ELISA)], whereas PR3-ANCA–negative
patients had titers of ≤1:20 (no detectable anti-PR3 by
ELISA) [10]. Furthermore, the authors observed no cor-
relation between ANCA titers and levels of IgG binding
to PMA-stimulated PMN. In our study, we used serum or
plasma samples from PR3-ANCA–positive WG patients
with PR3-ANCA titers ranging from 1:160 to 1:640, and
we observed a dose-dependent binding of IgG from PR3-
ANCA–positive patients to primed PMN.
Abdel-Salam et al used PMN stimulated with 1 lg/mL
phorbol myristate-acetate (PMA) as an up-regulator of
PR3 expression [10]. In most studies, effects of IgG bind-
ing have been studied in vitro using TNFa-primed PMN
[6, 7, 9, 17]. Therefore, we compared IgG binding in serum
and plasma from PR3-ANCA–positive WG patient to
TNFa-primed and PMA-stimulated PMN in parallel. We
observed significant binding of IgG in serum and plasma
samples from PR3-ANCA–positive WG patients both to
PMA-stimulated PMN and to TNFa-primed PMN.
In order to prove that binding of IgG from serum or
plasma from PR3-ANCA–positive patients was restricted
to mPR3-expressing PMN, we used donors who showed
bimodal PR3 expression on the membrane of their PMN.
Bimodal distribution of PR3 expression on PMN is a well-
established phenomenon [13, 14], representing the pres-
ence of 2 subsets of PMN within 1 donor: a subset of
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Fig. 5. Binding of IgG from plasma samples of PR3-ANCA–positive
patients is not dependent on Fcc-receptor interactions. Fcc-receptors
on TNFa-primed PMN from a donor with bimodal PR3 expression
were saturated by incubation with goat-derived heat-aggregated IgG
(0.5 mg/mL) for 15 minutes at 4◦C. Cells were subsequently washed in
PBS. Saturated and nonsaturated PMN were incubated for 30 minutes
at room temperature with undiluted plasma samples from PR3-ANCA–
positive patients (N = 3) and healthy controls (N = 3). Samples were
coincubated with mouse anti-PR3 MoAb to assess PR3-restricted bind-
ing, as described in Methods. Subsequently, cells were washed twice
and incubated with FITC-conjugated rabbit antihuman IgG and PE-
conjugated goat antimouse IgG. On the y-axis, mean fluorescence in-
tensity (MFI) values of binding experiments are depicted. Values are
given as mean ± standard error of the mean (SED).
PMN expressing PR3 on their membrane (mPR3+ PMN)
and a subset of PMN lacking expression of PR3 on their
membrane (mPR3− PMN) [10, 13, 14]. Furthermore, bi-
modal expression of PR3 is a unique and stable feature
of certain individuals, and is genetically determined [13,
14, 18]. Therefore, we performed double staining exper-
iments using mouse anti-PR3 MoAb together with IgG
from serum or plasma of PR3-ANCA–positive patients
in order to show that IgG from PR3-ANCA–positive pa-
tients bind to the same PMN as anti-PR3 MoAbs do, that
is, to mPR3+ PMN. The results led us to conclude that
IgG from PR3-ANCA–positive patients bind to mPR3+
PMN, implying binding to the same antigen as anti-PR3
MoAbs do. This conclusion is strengthened by the fact
that bimodal expression is only observed for PR3, and
not for elastase or other neutrophil markers [13, 14].
Abdel-Salam et al state that PR3-ANCA are low-
affinity antibodies. Next to the lack of specific binding
of ANCA to PMN in vivo and in vitro, this statement
was built upon the observation that binding of isolated
IgG from plasma of PR3-ANCA–positive patients to
PMN was inhibited by addition of 1:10 diluted serum,
human IgG, albumin, or by increasing the reaction vol-
ume [10]. However, the concentration of isolated IgG that
they used in their binding experiments (10–40 lg/mL)
was rather low compared to physiologic levels of IgG in
serum, which are around 10 to 15 mg/mL. Another ar-
gument against the low affinity nature of ANCA is the
functional interaction of PMN with ANCA-containing
serum, already demonstrated in 1990 by Falk et al [6].
They showed that incubation of TNFa-primed PMN with
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1:10 diluted ANCA-positive serum leads to activation of
these cells, resulting in degranulation and production of
oxygen radicals [6].
CONCLUSION
In the present study we demonstrate that PR3-ANCA
in undiluted serum or plasma from PR3-ANCA–positive
WG patients can bind to PMN that express membrane-
bound proteinase 3. Therefore, the hypothesis that PR3-
ANCA can bind and activate primed PMN, leading to
degranulation and oxygen radical production, is still the
most attractive in explaining the contribution of PR3-
ANCA to the pathogenesis of Wegener’s granulomatosis.
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